Silk Road Medical, Inc (NASDAQ:SILK) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA cut its holdings in Silk Road Medical, Inc (NASDAQ:SILK) by 0.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 278,717 shares of the company’s stock after selling 791 shares during the period. Massachusetts Financial Services Co. MA owned about 0.80% of Silk Road Medical worth $13,339,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Silk Road Medical in the first quarter valued at $25,000. US Bancorp DE raised its stake in Silk Road Medical by 120.4% in the second quarter. US Bancorp DE now owns 930 shares of the company’s stock valued at $44,000 after buying an additional 508 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Silk Road Medical by 34.4% in the second quarter. Great West Life Assurance Co. Can now owns 1,937 shares of the company’s stock valued at $93,000 after buying an additional 496 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Silk Road Medical by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,660 shares of the company’s stock valued at $127,000 after buying an additional 368 shares in the last quarter. Finally, Polar Capital Holdings Plc raised its stake in Silk Road Medical by 6.6% in the first quarter. Polar Capital Holdings Plc now owns 4,854 shares of the company’s stock valued at $246,000 after buying an additional 300 shares in the last quarter.

Shares of NASDAQ SILK opened at $53.97 on Thursday. Silk Road Medical, Inc has a 52-week low of $43.11 and a 52-week high of $75.80. The firm has a fifty day moving average of $55.71 and a 200-day moving average of $51.86. The stock has a market capitalization of $1.87 billion, a PE ratio of -38.01 and a beta of 1.51. The company has a quick ratio of 8.75, a current ratio of 9.51 and a debt-to-equity ratio of 0.51.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings results on Thursday, July 29th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. Silk Road Medical had a negative net margin of 53.85% and a negative return on equity of 45.52%. The firm had revenue of $26.46 million during the quarter, compared to analysts’ expectations of $25.33 million. Equities research analysts expect that Silk Road Medical, Inc will post -1.24 EPS for the current fiscal year.

SILK has been the topic of several research reports. SVB Leerink reaffirmed an “outperform” rating on shares of Silk Road Medical in a report on Tuesday, July 20th. Citigroup lowered Silk Road Medical from a “neutral” rating to a “sell” rating and set a $50.00 price objective on the stock. in a report on Friday, October 1st. Piper Sandler dropped their price objective on Silk Road Medical from $58.00 to $55.00 and set a “neutral” rating on the stock in a report on Friday, July 30th. Finally, Zacks Investment Research raised Silk Road Medical from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a report on Thursday, September 30th.

In other Silk Road Medical news, insider Andrew S. Davis sold 6,481 shares of the company’s stock in a transaction dated Wednesday, September 1st. The shares were sold at an average price of $59.71, for a total value of $386,980.51. Following the completion of the transaction, the insider now owns 71,188 shares in the company, valued at approximately $4,250,635.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Andrew S. Davis sold 6,324 shares of the stock in a transaction that occurred on Monday, August 2nd. The shares were sold at an average price of $50.75, for a total transaction of $320,943.00. Following the completion of the transaction, the insider now owns 37,115 shares of the company’s stock, valued at $1,883,586.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,536 shares of company stock valued at $5,221,542. 7.70% of the stock is owned by corporate insiders.

Silk Road Medical Profile

Silk Road Medical, Inc develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Further Reading: How does equity income fit into an investing strategy?

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.